alfuzosin has been researched along with Prostatism in 10 studies
alfuzosin: structure given in first source
Prostatism: Lower urinary tract symptom, such as slow urinary stream, associated with PROSTATIC HYPERPLASIA in older men.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to compare the efficacy and safety of alfuzosin (Alf) and tamsulosin (Tam) in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 9.15 | Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. ( Atahan, Ö; Budak, YU; Karadağ, E; Öner, S, 2011) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 7.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| "To evaluate the efficacy of alfuzosin treatment on voiding and storage in patients with lower urinary tract symptoms (LUTS)/benign prostatic hyperplasia (BPH) with respect to bladder outlet obstruction and contractility." | 5.15 | The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. ( Cho, JS; Choo, MS; Han, JY; Kim, JC; Lee, KS; Lee, YS; Song, K, 2011) |
| "The aim of this study was to compare the efficacy and safety of alfuzosin (Alf) and tamsulosin (Tam) in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)." | 5.15 | Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. ( Atahan, Ö; Budak, YU; Karadağ, E; Öner, S, 2011) |
| "To determine the effect of alfuzosin on sexual function by using the Male Sexual Health Questionnaire (MSHQ) in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH)." | 5.14 | An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. ( Cheon, J; Chung, BH; Chung, MK; Kim, MK; Kim, SW; Lee, JY; Lee, KS; Lee, SW; Park, JK; Park, K, 2010) |
| "To assess the 3-year efficacy and safety of the selective alpha(1)-blocker alfuzosin at 10 mg once daily in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in 'real-life practice'." | 3.74 | Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, RJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barkin, J | 1 |
| Diles, D | 1 |
| Franks, B | 1 |
| Berner, T | 1 |
| Fusco, F | 1 |
| Palmieri, A | 1 |
| Ficarra, V | 1 |
| Giannarini, G | 1 |
| Novara, G | 1 |
| Longo, N | 1 |
| Verze, P | 1 |
| Creta, M | 1 |
| Mirone, V | 1 |
| Roumeguère, T | 1 |
| Zouaoui Boudjeltia, K | 1 |
| Hauzeur, C | 1 |
| Schulman, C | 1 |
| Vanhaeverbeek, M | 1 |
| Wespes, E | 1 |
| Kim, MK | 1 |
| Cheon, J | 1 |
| Lee, KS | 2 |
| Chung, MK | 1 |
| Lee, JY | 1 |
| Lee, SW | 1 |
| Kim, SW | 1 |
| Chung, BH | 1 |
| Park, K | 1 |
| Park, JK | 1 |
| Song, K | 1 |
| Choo, MS | 1 |
| Han, JY | 1 |
| Lee, YS | 1 |
| Kim, JC | 1 |
| Cho, JS | 1 |
| Karadağ, E | 1 |
| Öner, S | 1 |
| Budak, YU | 1 |
| Atahan, Ö | 1 |
| Giannakopoulos, XK | 1 |
| Giotis, C | 1 |
| Karkabounas, SCh | 1 |
| Verginadis, II | 1 |
| Simos, YV | 1 |
| Peschos, D | 1 |
| Evangelou, AM | 1 |
| Geppetti, P | 1 |
| Nassini, R | 1 |
| Materazzi, S | 1 |
| Benemei, S | 1 |
| Nickel, JC | 1 |
| Vallancien, G | 1 |
| Emberton, M | 1 |
| Alcaraz, A | 1 |
| Matzkin, H | 1 |
| van Moorselaar, RJ | 1 |
| Hartung, R | 1 |
| Harving, N | 1 |
| Elhilali, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alfuzosin and Prostatism
| Article | Year |
|---|---|
α1-Blockers Improve Benign Prostatic Obstruction in Men with Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis of Urodynamic Studies.
Topics: Adrenergic alpha-1 Receptor Antagonists; Clinical Trials as Topic; Doxazosin; Humans; Indoles; Male; | 2016 |
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia?
Topics: Aged; Carbolines; Erectile Dysfunction; Humans; Imidazoles; Male; Middle Aged; Phosphodiesterase Inh | 2009 |
The concept of neurogenic inflammation.
Topics: Adrenergic alpha-Antagonists; Animals; Calcium Channels; Humans; Male; Nerve Tissue Proteins; Neurog | 2008 |
Role of alpha1-blockers in chronic prostatitis syndromes.
Topics: Adrenergic alpha-Antagonists; Anti-Infective Agents; Bacterial Infections; Chronic Disease; Clinical | 2008 |
4 trials available for alfuzosin and Prostatism
| Article | Year |
|---|---|
An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Ejaculation; Humans; Male; Middle Aged; Patient Satis | 2010 |
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Muscle | 2011 |
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Cross-Over Studies; Humans; Male; Middle Aged; Prosta | 2011 |
Effects of pulsed electromagnetic fields on benign prostate hyperplasia.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Electromagnetic Fields; Humans; Male; Organ Size; Pro | 2011 |
2 other studies available for alfuzosin and Prostatism
| Article | Year |
|---|---|
Alpha blocker monotherapy versus combination therapy with antimuscarinics in men with persistent LUTS refractory to alpha-adrenergic treatment: patterns of persistence.
Topics: Administrative Claims, Healthcare; Adrenergic alpha-Antagonists; Aged; Benzofurans; Doxazosin; Drug | 2015 |
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Topics: Adrenergic alpha-Antagonists; Aged; Disease Progression; Erectile Dysfunction; Humans; Male; Nocturi | 2008 |